safoof-e - muhazzil和奥利司他对肥胖和肥胖标志物的比较分析

Q2 Medicine

Obesity Medicine Pub Date : 2025-02-08 DOI:10.1016/j.obmed.2025.100589

Mohd Aslam , Ahmad Faraz , Zaki Ahmad Siddiqui , Maaz Ozair , Hamid Ashraf , Abdul Mannan

{"title":"safoof-e - muhazzil和奥利司他对肥胖和肥胖标志物的比较分析","authors":"Mohd Aslam , Ahmad Faraz , Zaki Ahmad Siddiqui , Maaz Ozair , Hamid Ashraf , Abdul Mannan","doi":"10.1016/j.obmed.2025.100589","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Obesity is truly a pandemic and associated with increased risk of multiple non-communicable diseases. The available pharmacotherapy of obesity is associated with multiple limitations. We have studied the effect of sufoof e muhazzil and compared it with orlistat in non-diabetic patients with obesity.</div></div><div><h3>Material and methods</h3><div>It was an open-label, interventional prospective study including 200 patients with obesity. These patients, aged between 18 and 60 years, had a body mass index (BMI) of 25–40 kg/m<sup>2</sup>. We divided them equally between the Sufoof e Muhazzil and Orlistat groups. The dose of sufoof e muhazzil was 6 gm/day, and orlistat was 120 mg twice daily for 2 months. We assessed the effect on weight, BMI, biochemical, and inflammatory markers at the onset and at the end of the study.</div></div><div><h3>Result</h3><div>The mean age, weight, BMI, and waist circumference were 37.85 years and 35.71 years, 80.7 kg and 74.9 kg, 32.7 kg/m<sup>2</sup> and 32.4 kg/m<sup>2</sup>, and 113.0 cm and 112.5 cm, respectively, for the orlistat and sufoof groups. There was a significant reduction in weight, BMI, and abdominal circumference in both groups (p value < 0.001 for all). Biochemical and inflammatory parameters also improved significantly in both groups. Sufoof e muhazzil use was associated with greater reductions in weight (5.8 vs 4.4 kg), BMI (2.5 vs 1.9 kg/m<sup>2</sup>) than orlistat.</div></div><div><h3>Conclusion</h3><div>Both orlistat and sufoof e muhazzil are associated with significant weight reduction and improvement in biochemical and inflammatory parameters. Both the drugs demonstrated excellent safety and tolerability.</div></div>","PeriodicalId":37876,"journal":{"name":"Obesity Medicine","volume":"54 ","pages":"Article 100589"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative analysis of safoof-e− muhazzil and orlistat on obesity and markers of obesity\",\"authors\":\"Mohd Aslam , Ahmad Faraz , Zaki Ahmad Siddiqui , Maaz Ozair , Hamid Ashraf , Abdul Mannan\",\"doi\":\"10.1016/j.obmed.2025.100589\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Obesity is truly a pandemic and associated with increased risk of multiple non-communicable diseases. The available pharmacotherapy of obesity is associated with multiple limitations. We have studied the effect of sufoof e muhazzil and compared it with orlistat in non-diabetic patients with obesity.</div></div><div><h3>Material and methods</h3><div>It was an open-label, interventional prospective study including 200 patients with obesity. These patients, aged between 18 and 60 years, had a body mass index (BMI) of 25–40 kg/m<sup>2</sup>. We divided them equally between the Sufoof e Muhazzil and Orlistat groups. The dose of sufoof e muhazzil was 6 gm/day, and orlistat was 120 mg twice daily for 2 months. We assessed the effect on weight, BMI, biochemical, and inflammatory markers at the onset and at the end of the study.</div></div><div><h3>Result</h3><div>The mean age, weight, BMI, and waist circumference were 37.85 years and 35.71 years, 80.7 kg and 74.9 kg, 32.7 kg/m<sup>2</sup> and 32.4 kg/m<sup>2</sup>, and 113.0 cm and 112.5 cm, respectively, for the orlistat and sufoof groups. There was a significant reduction in weight, BMI, and abdominal circumference in both groups (p value < 0.001 for all). Biochemical and inflammatory parameters also improved significantly in both groups. Sufoof e muhazzil use was associated with greater reductions in weight (5.8 vs 4.4 kg), BMI (2.5 vs 1.9 kg/m<sup>2</sup>) than orlistat.</div></div><div><h3>Conclusion</h3><div>Both orlistat and sufoof e muhazzil are associated with significant weight reduction and improvement in biochemical and inflammatory parameters. Both the drugs demonstrated excellent safety and tolerability.</div></div>\",\"PeriodicalId\":37876,\"journal\":{\"name\":\"Obesity Medicine\",\"volume\":\"54 \",\"pages\":\"Article 100589\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obesity Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2451847625000090\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2451847625000090","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

肥胖确实是一种流行病，与多种非传染性疾病的风险增加有关。现有的肥胖药物治疗存在多种局限性。我们研究了舒福穆哈齐尔对非糖尿病合并肥胖患者的疗效，并与奥利司他进行了比较。材料与方法该研究是一项开放标签、介入性前瞻性研究，纳入200例肥胖患者。这些患者年龄在18至60岁之间，体重指数（BMI）为25-40 kg/m2。我们将他们平均分配给Sufoof e Muhazzil和Orlistat两组。穆哈齐尔剂量为6 gm/d，奥利司他剂量为120 mg，每日2次，疗程2个月。我们在研究开始和结束时评估了对体重、BMI、生化和炎症指标的影响。结果奥利司他组平均年龄为37.85岁，体重为35.71岁，BMI为80.7 kg，腰围为74.9 kg, 32.7 kg/m2, 32.4 kg/m2, 113.0 cm, 112.5 cm。两组患者的体重、BMI和腹围均有显著降低(p值<；0.001)。两组患者的生化和炎症指标均有明显改善。与奥利司他相比，sufoofmuhazzil在体重（5.8 vs 4.4 kg）和BMI （2.5 vs 1.9 kg/m2）方面的降低幅度更大。结论奥利司他和穆哈齐均能显著减轻体重，改善生化和炎症指标。两种药物均表现出良好的安全性和耐受性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Comparative analysis of safoof-e− muhazzil and orlistat on obesity and markers of obesity

查看原文本刊更多论文

Comparative analysis of safoof-e− muhazzil and orlistat on obesity and markers of obesity

Introduction

Obesity is truly a pandemic and associated with increased risk of multiple non-communicable diseases. The available pharmacotherapy of obesity is associated with multiple limitations. We have studied the effect of sufoof e muhazzil and compared it with orlistat in non-diabetic patients with obesity.

Material and methods

It was an open-label, interventional prospective study including 200 patients with obesity. These patients, aged between 18 and 60 years, had a body mass index (BMI) of 25–40 kg/m². We divided them equally between the Sufoof e Muhazzil and Orlistat groups. The dose of sufoof e muhazzil was 6 gm/day, and orlistat was 120 mg twice daily for 2 months. We assessed the effect on weight, BMI, biochemical, and inflammatory markers at the onset and at the end of the study.

Result

The mean age, weight, BMI, and waist circumference were 37.85 years and 35.71 years, 80.7 kg and 74.9 kg, 32.7 kg/m² and 32.4 kg/m², and 113.0 cm and 112.5 cm, respectively, for the orlistat and sufoof groups. There was a significant reduction in weight, BMI, and abdominal circumference in both groups (p value < 0.001 for all). Biochemical and inflammatory parameters also improved significantly in both groups. Sufoof e muhazzil use was associated with greater reductions in weight (5.8 vs 4.4 kg), BMI (2.5 vs 1.9 kg/m²) than orlistat.

Conclusion

Both orlistat and sufoof e muhazzil are associated with significant weight reduction and improvement in biochemical and inflammatory parameters. Both the drugs demonstrated excellent safety and tolerability.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Obesity Medicine Medicine-Public Health, Environmental and Occupational Health

CiteScore

5.50

自引率

0.00%

发文量

审稿时长

40 days

期刊介绍： The official journal of the Shanghai Diabetes Institute Obesity is a disease of increasing global prevalence with serious effects on both the individual and society. Obesity Medicine focusses on health and disease, relating to the very broad spectrum of research in and impacting on humans. It is an interdisciplinary journal that addresses mechanisms of disease, epidemiology and co-morbidities. Obesity Medicine encompasses medical, societal, socioeconomic as well as preventive aspects of obesity and is aimed at researchers, practitioners and educators alike.